Spots Global Cancer Trial Database for A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Official Title: A Long-term Safety Study of the Pan-histone Deacetylase (HDAC) Inhibitor, PCI-24781, in Subjects With Cancer
Study ID: NCT01149668
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the long-term (\> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
Detailed Description: An open-label, monotherapy, multicenter, extension study open to subjects who have derived benefit from PCI 24781 PO for at least 6 months and want to continue receiving study drug. Subjects enrolled in this study will receive PCI-24781 at the schedule and dosage from their prior protocol. Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Northwestern Univ. Med School, Chicago, Illinois, United States
Horizon Oncology Center, Lafayette, Indiana, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Univ. of Nebraska Medical Center, Omaha, Nebraska, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Thorsten Graef, MD
Affiliation: Pharmacyclics LLC.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
